NCT02152982 2026-03-18
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
Clinical Trials
7 trialsNCT02595905 2025-05-16
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
Phase 2 Completed
NCT00994071 2019-12-09
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00770471 2018-06-27
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00649207 2017-11-21
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
AbbVie
Phase 1 Completed
NCT01026493 2017-07-02
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT00946335 2014-07-09
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
National Cancer Institute (NCI)
Phase 1 Completed